Hangkai Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hangkai Huang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chengfu Xu
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
4 shared publications - Yishu Chen
Department of Gastroenterology, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
2 shared publications - Zhening Liu
Department of Gastroenterology, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
2 shared publications - Chao Shen
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Jiarong Xie
Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China
1 shared publication - Jinghua Wang
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 30 December 2023
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 2 (4) , 157-164
Global burden trends of MAFLD‐related liver cancer from 1990 to 2019
Aims: Metabolic dysfunction‐associated fatty liver disease (MAFLD) has become a serious public health challenge and is a cause of liver cancer. Reports on the global epidemiology of MAFLD‐related liver cancer remain limited. This study aimed to estimate the global burden trends of MAFLD‐related liver cancer between 1990 and 2019.Methods: We estimated the numbers of global incident cases, deaths, and disability‐adjusted life years (DALYs) of MAFLD‐related liver cancer by analyzing data from the Global Burden of Disease Study 2019. We also analyzed the trends and regional and national differentials of MAFLD‐related liver cancer. Finally, we investigated the influential factors for the trends in MAFLD‐related liver cancer.Results: Globally, there were 36,340 (95% uncertainty interval [UI]: 29,490–44,860) incident cases, 34,730 (95% UI: 28,390–43,180) deaths, and 795,810 (95% UI: 657,290–975,790) DALYs of MAFLD‐related liver cancer in 2019, representing increases of 205%, 195%, and 166% compared with 1990, respectively. The age‐standardized incidence, mortality, and DALY rates per 100,000 population in 2019 were 0.44, 0.43, and 9.64, respectively. The most pronounced increases in incidence, deaths, and DALYs were consistently observed in countries with a high sociodemographic index. Increasing trends were noted in these three measures since 2005, and the trends were much greater in men than in women.Conclusions: MAFLD‐related liver cancer poses a substantial global burden that continues to grow. Undesirable trends were observed in countries with a high sociodemographic index.
- 30 December 2023
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 2 (4) , 157-164
Open AccessGlobal burden trends of MAFLD‐related liver cancer from 1990 to 2019
Aims: Metabolic dysfunction‐associated fatty liver disease (MAFLD) has become a serious public health challenge and is a cause of liver cancer. Reports on the global epidemiology of MAFLD‐related liver cancer remain limited. This study aimed to estimate the global burden trends of MAFLD‐related liver cancer between 1990 and 2019.Methods: We estimated the numbers of global incident cases, deaths, and disability‐adjusted life years (DALYs) of MAFLD‐related liver cancer by analyzing data from the Global Burden of Disease Study 2019. We also analyzed the trends and regional and national differentials of MAFLD‐related liver cancer. Finally, we investigated the influential factors for the trends in MAFLD‐related liver cancer.Results: Globally, there were 36,340 (95% uncertainty interval [UI]: 29,490–44,860) incident cases, 34,730 (95% UI: 28,390–43,180) deaths, and 795,810 (95% UI: 657,290–975,790) DALYs of MAFLD‐related liver cancer in 2019, representing increases of 205%, 195%, and 166% compared with 1990, respectively. The age‐standardized incidence, mortality, and DALY rates per 100,000 population in 2019 were 0.44, 0.43, and 9.64, respectively. The most pronounced increases in incidence, deaths, and DALYs were consistently observed in countries with a high sociodemographic index. Increasing trends were noted in these three measures since 2005, and the trends were much greater in men than in women.Conclusions: MAFLD‐related liver cancer poses a substantial global burden that continues to grow. Undesirable trends were observed in countries with a high sociodemographic index.
- Open Access
Dietary Patterns and Long-Term Outcomes in Patients with NAFLD: A Prospective Analysis of 128,695 UK Biobank Participants
Large longitudinal studies exploring the role of dietary patterns in the assessment of long-term outcomes of NAFLD are still lacking. We conducted a prospective analysis of 128,695 UK Biobank participants. Cox proportional hazards models were used to estimate the risk associated with two dietary patterns for long-term outcomes of NAFLD. During a median follow-up of 12.5 years, 1925 cases of end-stage liver disease (ESLD) and 12,466 deaths occurred in patients with NAFLD. Compared with patients in the lowest quintile, those in the highest quintile of the diet quality score was negatively associated with the risks of ESLD and all-cause mortality (HRQ5vsQ1: 0.76, 95% CI: 0.66–0.87, p < 0.001; HRQ5vsQ1: 0.84, 95% CI: 0.79–0.88, p < 0.001, respectively). NAFLD patients with high-quality carbohydrate patterns carried a 0.74-fold risk of ESLD and a 0.86-fold risk of all-cause mortality (HRQ5vsQ1: 0.74, 95% CI: 0.65–0.86, p < 0.001; HRQ5vsQ1: 0.86, 95% CI: 0.82–0.91, p < 0.001, respectively). For prudent dietary patterns rich in vegetables, fruits and fish, the adjusted HR Q5vsQ1 (95% CI) was 0.87 (0.76–0.99) and 0.94 (0.89–0.99) for ESLD and all-cause mortality of NAFLD patients. There was a U-shaped association between the meat-rich dietary pattern and all-cause mortality in patients with NAFLD. These findings suggest that a diet characterized by a high-quality, high intake of vegetables, fruits, fish and whole grains as well as an appropriate intake of meat, was associated with a lower risk of adverse outcomes of NAFLD.
Open AccessDietary Patterns and Long-Term Outcomes in Patients with NAFLD: A Prospective Analysis of 128,695 UK Biobank Participants
Large longitudinal studies exploring the role of dietary patterns in the assessment of long-term outcomes of NAFLD are still lacking. We conducted a prospective analysis of 128,695 UK Biobank participants. Cox proportional hazards models were used to estimate the risk associated with two dietary patterns for long-term outcomes of NAFLD. During a median follow-up of 12.5 years, 1925 cases of end-stage liver disease (ESLD) and 12,466 deaths occurred in patients with NAFLD. Compared with patients in the lowest quintile, those in the highest quintile of the diet quality score was negatively associated with the risks of ESLD and all-cause mortality (HRQ5vsQ1: 0.76, 95% CI: 0.66–0.87, p < 0.001; HRQ5vsQ1: 0.84, 95% CI: 0.79–0.88, p < 0.001, respectively). NAFLD patients with high-quality carbohydrate patterns carried a 0.74-fold risk of ESLD and a 0.86-fold risk of all-cause mortality (HRQ5vsQ1: 0.74, 95% CI: 0.65–0.86, p < 0.001; HRQ5vsQ1: 0.86, 95% CI: 0.82–0.91, p < 0.001, respectively). For prudent dietary patterns rich in vegetables, fruits and fish, the adjusted HR Q5vsQ1 (95% CI) was 0.87 (0.76–0.99) and 0.94 (0.89–0.99) for ESLD and all-cause mortality of NAFLD patients. There was a U-shaped association between the meat-rich dietary pattern and all-cause mortality in patients with NAFLD. These findings suggest that a diet characterized by a high-quality, high intake of vegetables, fruits, fish and whole grains as well as an appropriate intake of meat, was associated with a lower risk of adverse outcomes of NAFLD.
- Open Access
- 7 December 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021, 1-7
Association between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
Background. The aim of the present study was to investigate the association between monocyte to high-density lipoprotein cholesterol ratio (MHR) and nonalcoholic fatty liver disease (NAFLD) in Chinese population. Methods. We enrolled 14189 individuals who attended their annual health examinations in the study. We performed the anthropometric and laboratory measurements and diagnosed NAFLD by hepatic ultrasonography without evidence of other etiologies of chronic liver disease. Student’s -test, Mann–Whitney test, and chi-squared (χ2) test was used to compare the differences of clinical characteristics between participants with or without NAFLD. Pearson’s and Spearman’s analyses were performed to assess the correlation of MHR and NAFLD risk factors. Univariate and multivariate logistic regression analyses were conducted to explore whether MHR associated with NAFLD. Results. Thirty-five percent of the participants enrolled were diagnosed with NAFLD. Compared with healthy controls, NAFLD patients were male predominant, older, and had higher body mass index, waist circumference, and systolic and diastolic blood pressure, as well as higher levels of alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, glycated hemoglobin A1c, and serum uric acid, but lower levels of serum high-density lipoprotein cholesterol. Besides, MHR was significantly higher in NAFLD patients than healthy controls [5.35 (4.18–6.84) versus 4.53 (3.48–5.93), ]. MHR quartiles were positively related to the prevalence of NAFLD ( for trend). In multivariate logistic regression analysis, MHR was positively associated with the risk of NAFLD after adjusting age, gender, body mass index, waist circumference, diastolic blood pressure, alanine aminotransferase, triglyceride, total cholesterol, fasting plasma glucose, and serum uric acid (OR: 1.026, 95% CI: 1.002–1.052; ). Conclusions. MHR is significantly and positively associated with the risk of NAFLD.
- 7 December 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021, 1-7
Open AccessAssociation between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
Background. The aim of the present study was to investigate the association between monocyte to high-density lipoprotein cholesterol ratio (MHR) and nonalcoholic fatty liver disease (NAFLD) in Chinese population. Methods. We enrolled 14189 individuals who attended their annual health examinations in the study. We performed the anthropometric and laboratory measurements and diagnosed NAFLD by hepatic ultrasonography without evidence of other etiologies of chronic liver disease. Student’s -test, Mann–Whitney test, and chi-squared (χ2) test was used to compare the differences of clinical characteristics between participants with or without NAFLD. Pearson’s and Spearman’s analyses were performed to assess the correlation of MHR and NAFLD risk factors. Univariate and multivariate logistic regression analyses were conducted to explore whether MHR associated with NAFLD. Results. Thirty-five percent of the participants enrolled were diagnosed with NAFLD. Compared with healthy controls, NAFLD patients were male predominant, older, and had higher body mass index, waist circumference, and systolic and diastolic blood pressure, as well as higher levels of alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, glycated hemoglobin A1c, and serum uric acid, but lower levels of serum high-density lipoprotein cholesterol. Besides, MHR was significantly higher in NAFLD patients than healthy controls [5.35 (4.18–6.84) versus 4.53 (3.48–5.93), ]. MHR quartiles were positively related to the prevalence of NAFLD ( for trend). In multivariate logistic regression analysis, MHR was positively associated with the risk of NAFLD after adjusting age, gender, body mass index, waist circumference, diastolic blood pressure, alanine aminotransferase, triglyceride, total cholesterol, fasting plasma glucose, and serum uric acid (OR: 1.026, 95% CI: 1.002–1.052; ). Conclusions. MHR is significantly and positively associated with the risk of NAFLD.
- Open Access
- 4 June 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-6
Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
Background. This study aimed to explore the association between high-density lipoprotein cholesterol to apolipoprotein A-I ratio (HDL-C/apo A-I) and nonalcoholic fatty liver disease (NAFLD). Methods. A total of 9025 Chinese adults were enrolled in this cross-sectional study, who presented their annual health checkups at Zhenhai Lianhua Hospital, Ningbo, during 2017. Results. The NAFLD prevalence was 33.7%, and HDL-C/apo A-I was significantly decreased in NAFLD patients, as well as in lean NAFLD and in patients with NAFLD-related advanced fibrosis (all ). The prevalence of NAFLD and components of metabolic syndrome are inversely associated with HDL-C/apo A-I ( ). Multivariate logistic regression analysis show that HDL-C/apo A-I is inversely associated with the risk of NAFLD (odds ratio: 0.353, 95% confidence interval: 0.257–0.486; ). Conclusions. Our results suggested that increased HDL-C/apo A-I is significantly associated with a decreased risk of NAFLD.
- 4 June 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-6
Open AccessAssociation between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
Background. This study aimed to explore the association between high-density lipoprotein cholesterol to apolipoprotein A-I ratio (HDL-C/apo A-I) and nonalcoholic fatty liver disease (NAFLD). Methods. A total of 9025 Chinese adults were enrolled in this cross-sectional study, who presented their annual health checkups at Zhenhai Lianhua Hospital, Ningbo, during 2017. Results. The NAFLD prevalence was 33.7%, and HDL-C/apo A-I was significantly decreased in NAFLD patients, as well as in lean NAFLD and in patients with NAFLD-related advanced fibrosis (all ). The prevalence of NAFLD and components of metabolic syndrome are inversely associated with HDL-C/apo A-I ( ). Multivariate logistic regression analysis show that HDL-C/apo A-I is inversely associated with the risk of NAFLD (odds ratio: 0.353, 95% confidence interval: 0.257–0.486; ). Conclusions. Our results suggested that increased HDL-C/apo A-I is significantly associated with a decreased risk of NAFLD.